China–US joint-venture drug discovery and development company founded in 2012, focused on innovative small-molecule medicines for metabolic and inflammatory diseases, including diabetes and gout, as well as cancer
China–US joint-venture drug discovery and development company founded in 2012, focused on innovative small-molecule medicines for metabolic and inflammatory diseases, including diabetes and gout, as well as cancer. Its ABP-671 gout treatment has reported positive Phase II efficacy and safety results.